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Abstract
Natural compounds capable of inducing apoptosis in cancer cells have always been of considerable interest as
potential anti-cancer agents. Many such compounds are under screening and development with their potential
evolution as a clinical drug benefiting many of the cancer patients. Guggulsterone (GS), a phytosterol isolated gum
resin of the tree Commiphora mukul has been widely used in Indian traditional medicine as a remedy for various
diseses. GS has been shown to possess cancer chemopreventive and therapeutic potential as established by in vitro
and in vivo studies. GS has been shown to target constitutively activated survival pathways such as PI3-kinase/AKT,
JAK/STAT, and NFκB signaling pathways that are involved in the regulation of growth and inflammatory responses
via regulation of antiapoptotic and inflammatory genes. The current review focuses on the molecular targets of GS,
cellular responses, and the animal model studies in various cancers. The mechanistic action of GS in different types
of cancers also forms a part of this review. The perspective of translating this natural compound into a clinically
approved drug with its pros and cons is also discussed.
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Background
The important aspect in cancer chemoprevention is to
identify drugs or compounds that kill the tumor cells
with lower toxicity to healthy tissue. The other alterna-
tive approach could be to identify agents, which either
slows or even halts the tumor progression. The growing
evidence linked the deregulation of apoptosis in cancer
cells and supports the hypothesis that targeting
deregulated apoptotic signaling pathways could serve
as a tool for cancer prevention [1, 2]. Interestingly, the
chemotherapeutic drugs that are currently used exert
their cytotoxic effect through the induction of apop-
tosis [3–5]. Therefore, the success of cancer therapy
depends on the sensitivity of cancer cells to respond to
the therapeutic agents that turn on the apoptotic
process. The signaling cascade that leads to apoptosis
can be induced by a vast variety of drugs with diverse
chemical structures and different mechanisms of ac-
tion, notably through the inhibition of survival and
increased expression of pro-apoptotic genes. Natural
compounds have been shown to have less cytotoxicity
and efficient in blocking prosurvival/ growth signal
transduction pathways. Interestingly, most of the nat-
ural compounds currently available as pharmaceutical
products isolated from plant extracts have proven to
exhibit anti-tumor properties in vivo and in vitro. One
such traditional medicine, guggulsterone (GS), [4,
17(20)-pregnadiene- 3, 16-dione], a plant polyphenol
extracted from the gum resin of the Commiphora
mukul tree has been broadly used for centuries to treat
multiple human diseases [6–8]. The active ingredients
found in the extract from the gum resin of Mukul tree
are the isomers E- and Z-GS (Fig. 1) and both these
forms have been extensively used to treat multiple dis-
orders. It has been shown that GS is an antagonist of
bile acid farnesoid X receptor (FXR) [9–11] and inhib-
ition of FXR expression by GS causes anticancer activ-
ity in many cancer cells [12–17]. There is also
accumulating evidence about the role of GS in choles-
terol homeostasis regulation by increasing the tran-
scription of bile salt export pump [10, 11, 17]. GS has
been shown to play an important role in nutritional
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metabolism as it has been found to inhibit cholesterol
synthesis in the liver via antagonism of the FXR and
the bile-acid receptor [18]. GS has been widely used
for the treatment of hyperlipidemia in humans [5, 19].
A number of studies have demonstrated that GS effi-
ciently decreases low density lipoprotein cholesterol
and triglyceride levels in serum and increases high
density lipoprotein cholesterol levels [20, 21]. Specific-
ally, E and Z isoforms of GS have been identified as ac-
tive ingredients for lipid-lowering [22]. GS has been
shown to bind FXR and prevent the expression of FXR
agonist-mediated genes [8, 23]. Furthermore, it has
been demonstrated that the lipid lowering effect of GS
in liver are due to inhibition of FXR as confirmed from
FXR knockout mice studies [8].
GS has been found to induce apoptotic cell death in
many types of cancer [24–28] via activation of caspases,
increased expression of genes of Bcl-2 family members
and generation of reactive oxygen intermediates. A num-
ber of studies have shown that GS strongly inhibits the
activation of various survival signaling pathways includ-
ing, PI3-kinase/AKT, JAK/STAT and nuclear factor-kB
(NF-kB) in various cancer cells [29–31] (Table 1). Con-
stitutive activity of NF-kB plays a crucial role in growth
and proliferation of malignant cells via regulating
expression of several antiapoptotic genes. GS was found
to efficiently suppress the expression of these antiapop-
totic genes in many cancer cells (Fig. 2). In addition, GS
has also been shown to suppress the ionizing radiation
(IR)-mediated activation of NF-κB and augments the ra-
diosensitivity of human cancer cell lines [32]. Further,
GS is reported to reduce cell growth as well as prevents
IR-induced DNA damage repair [32] and GS has been
shown to induce apoptosis in a wide rangeof cancer cells
Table 1 Anticancer activity of GS in in vitro experimental model and underlying molecular targets
Cancer Type Model/System Molecular Targets References
Pancreatic cancer Human pancreatic cancer cell lines ↓FXR reduced ↓ NF-κB, ↓Cyclin D1, ↓Bcl-2, ↓XIAP↓MPP9, ↓STAT3,
↓FAK, ↓Src, p-AKT,c-June, ↑Caspase-3,↑Bax
[33, 38, 39]
Head and Neck cancer Head and neck carcinoma cell line ↓ PI3-kinase/AKT, ↑Bax, ↑Bad [88]
Esophagael cancer Esophageal adenocarcinoma cell lines ↓caudal type homeobox 2,↓Cox2,↓NFkB, ↓FXR, ↓ RAR-β2,
↑caspase-8,caspase-9,caspase-3
[47, 48]
Colon cancer Colon cancer cell line ↓cIAP-1, ↓cIAP-2, ↓Bcl-2, ↓STAT3, ↓VEGF, ↑truncated Bid, ↑Fas,
↑p-JNK, ↑p-c-Jun
[50, 51]
Breast cancer Breast cancer cell lines ↓cyclin D1, ↓C-myc, ↓survivin, ↓TCF-4, ↓IKK/NF-κB,
↓MAPK/AP-1, ↓MMP-9 ↓
[34, 89]
Prostate cancer Prostate cancer cell lines ↑caspase-9, ↑caspase-8, ↑caspase-3, ↑Bax
↓Bcl-2 and ↓Bcl-xL
[27]
Hepatocellular carcinoma Hepatocellular carcinoma cell lines ↓TGF-β1, ↓VEGF,↓ Bcl-2,↑Bax,
↓ NF-κB, ↓STAT3
[83, 85]
Hematological malignancies Leukemic cell lines ↓Bfl-1/A1, ↓XIAP, ↓cFLIP, ↓Bcl-2, ↓BclXL, ↓survivin
↑caspase 8, ↑bid cleavage, ↑cytochrome c release, ↑caspase 9,
↑ caspase 3, ↑ PARP cleavage.
[25]
Fig. 1 a The Plant Commiphora mukul. The chemical structure of Guggulsterone isoforms, E-Guggulsterone (b) and Z-Guggulsterone (c)
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[24, 25, 27, 28, 33–36]. The detailed molecular targets of
GS and mechanisms regulating apoptosis in various can-
cers are discussed in this review.
Guggulsterone and cancer
Since several decades extensive research has revealed
that many chronic illnesses are caused by the deregula-
tion of multiple genes mainly involved in cell cycle con-
trol enabling the cells to divide uncontrollably leading to
metastasis [1–4]. Most of the conventional drugs pri-
marily target a single gene product or signaling pathway
at a given time, thus having a limited scope for the treat-
ment. In addition these medicines exhibit many toxic
side effects. Due to these limitations, there is a growing
trend towards alternative medicines such as traditional
medicine derived from natural compounds which are
safe and have broad spectrum activity [37]. GS is one
such ancient medicine that targets multiple signaling
molecules with a varied range of mechanisms with its
proven antiproliferative and proapoptotic effects in vitro
and in vivo studies (Tables 1 and 2). The following sec-
tions describe GS-mediated anticancer effects and its
potential targets in various cancers.
Pancreatic cancer
Pancreatic tumors are highly aggressive, and there is an
urgent need of therapeutic strategy for the better man-
agement of this cancer. The existing chemotherapeutic
drugs cause high toxicity and drug resistance. Macha et
al. [33] using in vitro model have shown that GS pre-
vents cell proliferation, inhibits cell motility reduces cell
invasion and induces apoptotic cell death in many
Fig. 2 Biochemical and molecular targets of Guggulsterone. Guggulsterone exerts anti-cancer effects through activation or suppression of protein
kinases, transcription factors, anti-oxidant enzymes, cell cycle regulators, proapoptotic and antiapoptotic proteins. GS exerts anti-inflammatory
effects through suppression of nuclear factor-kB (NF-kB), which plays a crucial role in the inflammatory processes by regulating the expression
of diverse proinflammatory proteins, including cyclooxygenase-2 (COX-2). GS fortifies cellular defense against oxidative stress by inducing the de
novo synthesis of the powerful antioxidant enzyme heme oxygenase-1 (HO-1). GS induces apoptosis by increasing the expression of proapoptotic
proteins while decreasing the levels of antiapoptotic proteins (e.g., IAP1, XIAP, Bfl-1/A1, Bcl-2, cFLIP, Survivin, etc.). GS induces apoptosis by increasing
the expression of proapoptotic proteins while decreasing the levels of antiapoptotic proteins (e.g., IAP1, XIAP, Bfl-1/A1, Bcl-2, cFLIP, Survivin, etc.). GS
suppresses invasion and metastasis by targeting MMPs, FXR etc
Table 2 Anticancer activity of GS in in vivo animal experimental models
Cancer Type Model/System Antitumor effects References
Pancreatic cancer Pancreatic cancer cell line xenograft tumors ↓ tumor size [39]
Colon Cancer HT-29 xenograft tumors ↓ tumor size [50]
Esophageal cancer Esophageal adenocarcinoma cell lines ↓ tumor size [47]
Breast cancer MCF7 xenograft tumors ↓Bcl-2 and P-glycoprotein expression
↑Chemosensivity of doxorubicin in vivo
[75]
Prostate cancer DU145 prostate cancer cells implanted in mouse ↓ tumor size, ↓ angiogenesis↓ VEGFR-2 [28]
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pancreatic cancer cell lines. The anti-cancer activity of
GS was correlated with the down-regulation of anti-
apoptotic proteins, cell cycle progression proteins and
up-regulation of proapoptotic proteins. Furthermore, the
reduced motility and suppressive effects on invasion in
pancreatic cancer cells by GS were associated with the
disruption of cytoskeletal organization, inhibition of
FAK and Src kinase signaling. GS treatment was also
found to reduce mucin MUC4 gene expression by inhib-
ition of JAK kinase mediated signaling [33]. A recent
study using pancreatic cancer cell lines has reported a
significant reduction in cell migration and invasion by
GS-mediated FXR inhibition indicating the potential role
of FXR overexpression in lymphatic metastasis of pan-
creatic cancer [38].
GS has been found to increase the sensitivity of con-
ventional chemotherapeutic agents such as gemcitabine.
Treatment of pancreatic cancer cells with GS augmented
apoptotic cell death when combined with gemcitabine as
compared to treatment either with gemcitabine or GS
alone. In addition, the tumors from xenografted mice in
vivo model showed a better antitumor response to GS
combination treatment compared to gemcitabine or GS
alone.
Studies from in vitro and in vivo (Tables 1 and 2) set-
tings have shown that the combination treatment leads
to increased growth inhibition as well as apoptosis
through a cascade of events involving the down-
regulation of NF-κB, inhibition of AKT activity, down-
regulation of antiapoptotic gene BcL-2, upregulation of
proapoptotic gene Bax and, activation of c-Jun NH(2)-
terminal kinase (JNK) [39].
Head and neck cancer
A number of studies provide substantial evidence that
GS suppressed the growth/or induced apoptotic cell
death of head and neck squamous cell carcinoma
(HNSCCC) [40–42]. GS-mediated inhibition of HNSCC
proliferation is caused by inactivation of NF-κB and
STAT3 signaling cascades. GS treatment of HNSCC cells
prevents NF-κB activation and leads to its degradation
resulting in the inhibition of inflammatory and angio-
genic responses as well as progression and metastasis
[35, 36]. GS was also able to inhibit COX-2 and vascular
endothelial growth factor (VEGF) which contributes to
inflammation and angiogenesis [35]. The antiprolifera-
tive and pro-apoptotic action of GS in SCC4 cells has
been due to downregulation of various antiapoptotic
genes including Bcl-2, XIAP, Mcl1, survivin, cyclin D1
and c-myc. Furthermore GS-mediated downregulation
of these genes resulted sequential activation of caspas-
9,-3 and cleavage, of poly-ADP-ribose phosphate (PARP)
[25, 43].
Recently it has been reported that combination of
GS and bortezomib, a proteasome inhibitor synergize
the inhibition of signaling molecules that are essential
for the proliferation and survival of malignant cells
[44, 45]. These reports further suggest that co-
treatment of HNSCC cells with bortezomib and GS
potentiated effects on cell death and inhibited clono-
genic survival. These findings correlated with inhib-
ition of NF-κB signaling pathway [44] and induction of
the proapoptotic proteins Bik, Bim, and Noxa [45].
These results suggest that GS could significantly im-
prove the therapeutic activity of bortezomib against
HNSCC in cotreatment strategy. Similar studies with
erlotinib, cetuximab, and cisplatin in HNSCC cell lines
further supported the synergistic activity of GS to-
wards enhanced efficacy to apoptosis, cell cycle arrest
and invasion [46].
Esophageal adenocarcinoma
Chronic Gastroesophageal Reflux Disease (GERD) is
the main risk factor for the development of Barrett's
esophagus (BE) and its progression to esophageal
adenocarcinoma (EAC). Studies have shown the
significant overexpression of bile acid receptor FXR in
Barrett's esophagus and treatment of Barrett's
esophagus-derived cell line with GS was found to sig-
nificantly reduce the expression of FXR.. Treatment of
Barrett's esophagus-derived cell line with GS was
linked with a significant increase in the percentage of
apoptotic cells and of the caspase -3 activity signifying
that FXR may contribute to the regulation of apoptosis
[12]. A similar study further showed that the inhib-
ition of FXR in esophageal adenocarcinoma tissues ei-
ther with an expression of FXR shRNA or treatment
with GS suppressed tumor cell viability and induced
apoptosis in vitro and in vivo [16] suggesting GS as a
potential antagonist to FXR overexpression and a can-
cer chemotherapeutic. GS has been shown to have
additive effect in suppressing esophageal cancer cell
growth in vitro and in nude mouse xenografts when
combined with amiloride and this activity is due to the in-
hibition of gastric acid-inducing gene Na + /H + exchan-
ger-1 (NHE-1) [47]. In another study, GS has been shown
to suppress bile acid induced caudal type homeobox 2
(CDX2) and cyclooxygenase-2 (COX-2) expression, which
are critical in the development of Barrett’s Esophagus and
esophageal adenocarcinoma and this effect is due to inhib-
ition of NF-kB activity [48].
Colon cancer
Although there is a major progress in the advancement
of chemotherapeutic agents for the treatment of colon
cancer, however, the relapse rates still remain to be ele-
vated for the existing drugs. The current chemotherapy
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has been benefecial only to the patients with advanced
colorectal cancerregarding their survival and quality of
life [49]. The other problems that happen to be with the
conventional chemotherapy are systemic side effects and
increased chemoresistance. Because of these limitations,
there is an urgent need for more efficient and safer
therapeutic strategies for advanced or untreatable colo-
rectal cancer. Interestingly, a considerable amount of
attention towards the anti-tumor properties of various
phytochemicals has developed in the last few years both
in vivo and in vitro. In connection to this, GS was
found to possess potential anti-tumor effects in several
cancer cell types including colorectal cancer [24–28,
33]. Emerging studies have also demonstrated that GS
and its derivatives significantly reduced dextran sulfate
sodium (DSS)-induced acute murine colitis. Further,
more this effect was found due to GS-mediated down-
regulation of NF-kB signaling pathway. These findings
suggest that GS- mediated targeting of signaling path-
ways may be an attractive strategy for the treatment of
inflammatory bowel disease (IBD) [30]. GS has also
been shown to induce apoptotic cell death via activa-
tion of caspase cascade, downregulation of inhibitor of
apoptosis proteins Bcl-2, and activation of JNK kinase
[50]. GS treatment of colon cancer cell lines has been
shown to block angiogenesis and metastasis by inactiva-
tion of STAT3 activity and downregulation of VEGF ex-
pression [51].
Bile acid receptor FXR besides playing a role in lipid
metabolism, has also been shown to play an important
role in intestinal carcinogenesis. Reduced expression of
FXR mRNA has been found in human colon polyps
and even more pronounced in colon adenocarcinomas
[52, 53]. FXR has been shown to suppress intestinal
tumorigenesis in both the ApcMin+/− and chronic colitis
mouse models of intestinal neoplasia by regulating Wnt
signaling and apoptosis [54]. FXR-deficient mice have
been shown to exhibit increased intestinal epithelial cell
proliferation and tumor development [55]. Recently,
Peng et al. [15] have demonstrated that treatment of
colon cancer cell lines with FXR antagonist GS or FXR
siRNA lead to phosphorylation of EGFR and ERK
whereas treatment with GW4064 or FXR overexpres-
sion prevented cell proliferation by dephosphorylation
of EGFR and ERK. In addition treatment of colon can-
cer cell lines with GS and GW4064 also caused dose-
dependent changes in Src (Tyr416) phosphorylation.
Breast cancer
Advanced early screening as well as detection methods
have been developed, and several are under development
for various cancers, including breast cancer. However,
breast cancer continues to be the most challenging
owing to its high frequency among women worldwide
[56, 57]. A number of studies have suggested that vari-
ous mechanisms are responsible for the incidence and
development of breast carcinogenesis. NF-κB pathway is
highly activated in breast cancer [58, 59]. NF-κB is one
of the key molecules shown to regulate the expression of
various antiapoptotic genes that plays a crucial role in
tumorigenesis [29, 60]. These genes are bcl-2, and bcl-xl,
adhesion molecule encoding genes, chemokines, and in-
flammatory cytokines; and cell cycle regulators. There-
fore, targeting NF-κB and its associated partners could
be an important therapeutic strategy for the manage-
ment of breast cancer. Previously it has been demon-
strated that GS inhibits NF-κB activation via IκBα
kinase suppression, along with the dephosphorylation
and degradation of IκBα. Moreover, GS also interferes
nuclear translocation of p65 and NF-κB- mediated re-
porter gene activity [29]. GS treatment of cancer cells
has been found to abrogate the expression of NF-κB-
mediated antiapoptotic genes, as well the genes involved
in regulation of inflammation and tumor metastasis
[29–31]. Activation of pro-survival signaling pathways
play a crucial role in suppression of apoptotic cell death
during radiosensitization of cancer cells [61]. Ionizing
radiation (IR) has been found to activate NF-κB and as-
sociated pathways that are involved in growth and sur-
vival of cancer cells [62]. Interestingly, GS treatment
abrogated the IR-mediated activation of NF-κB and aug-
mented the radiosensitivity of human tumor cell lines.
Expression of hormone receptors by breast cancer cells
makes them sensitive to hormonal therapy. However, the
use of ER antagonists is restricted due to unwanted side
effects [58]. Therefore, the development of new, safe and
affordable therapeutics against ER-breast cancer cells
harboring ER as well is much needed. GS has been
found to downregulate the expression of ERα in breast
cancer cells implicating that it could be a viable thera-
peutic useful in the treatment of ER-positive tumors that
are resistant to tamoxifen [32].
It has been shown that the isomer of GS, cis-GS pre-
vented TPA-upregulated MMP expression via obstruct-
ing IKK/NF-kB signaling. On the other hand, trans-GS
was found to inhibit MAPK/AP-1 signaling pathway in
MCF7 breast cancer cell line. Furthermore, co-treatment
of breast cancer cells with these isomers exhibited addi-
tive effects on the inhibition of cell invasion. Another
key signaling in growth and development of tumors is
the Wnt/β-Catenin and its associated pathways [34].
This pathway has been shown to play a significant role
in the initiation, progression, and metastasis of breast
cancers [63–65]. The Wnt signaling exerts its effects on
TCF-mediated transcription via β-Catenin [63–66].
Therefore, intercepting the signaling between Wnt and
β-Catenin may prove a better way in developing new
cancer therapeutics. Research in this direction, using
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natural products have already been shown to be promis-
ing [67–69]. It has been demonstrated that the expres-
sion of c-Myc, cyclin D1, and survivin, downstream of
Wnt/β-Catenin signaling, were inhibited by guggulipid
(GL) and z-GS in breast cancer significantly. In
addition, treatment with GL in human breast cancer
cells results in downregulation of TCF-4 protein ex-
pression significantly.
DNA methylation, as well as histone modifications,
are other attractive targets for therapeutics strategy for
the management of cancer [70]. Deregulated methyla-
tion can result in silencing of various functional genes
including tumor suppressors that often lead to cancer
development and progression [70]. Inhibition of DNA
methyltransferases has been shown to suppress tumor
formation [71]. Interestingly, some epigenetic modifica-
tions that regulate normal cellular activity via dietary
phytochemicals have proved to be reducing cancer sus-
ceptibility [72]. It has been demonstrated that GS treat-
ment of breast cancer cells inhibits the expression of
DNA (cytosine-5)-methyltransferase 1(DNMT1) and
HDAC1 [73].
Current chemotherapy for breast cancer faces a major
problem of drug resistance. A viable approach to avoid
drugs causing drug resistance is by utilizing non-toxic
compounds in combination with conventional chemo-
therapeutic agents. Xu et al. [74] have reported that
multidrug resistance developed by the expression of P-
glycoprotein in breast cancer cells (MCF/Dox) against
doxorubicin can be improved by treatment with GS.
Co-treatment of MCF/DOX cells with GS and doxo-
rubicin results in a significant increase in chemosensi-
tivity. A similar observation was found in xenografts
generated from MCF-7/DOX cells [75]. BCRP/ABCG2,
an ABC transporter is overexpressed in breast cancer
cells and has been shown to be involved in multidrug
resistance [76]. Combined treatment of GS with bexar-
otene a retinoid X receptor agonist resulted in cytotox-
icity via downregulation of BCRP/ABCG2 in breast
cancer cell line.
Prostate cancer
Prostate cancer progression is a slow multistep process
which begins with localized and low-grade lesions to
high-grade and metastatic carcinomas resulting in a sig-
nificant number of deaths in men [77, 78]. The slow
progression and late diagnosis of prostate cancer allow a
substantial opportunity for intervention to prevent this
malignancy [79].
There are a considerable number of preclinical studies
showing the anticancer activity of GS in prostate can-
cers. Singh and colleagues [24], have demonstrated that
the GS treatment of human prostate cancer cell line,
PC-3 resulted in efficient cytotoxic effects without
affecting the normal prostate epithelial cell line (PrEC).
In addition, GS-mediated growth inhibition of PC-3 cells
occurs due to apoptosis rather than the cell cycle pro-
gression arrest. Furthermore, GS-induced apoptotic cell
death correlated with the enhanced expression of Bcl-2
family members such as Bax and Bak and sequential ac-
tivation of caspase cascade [27]. Furthermore, Xu and
Sing [28] reported that z-GS treatment of DU145 im-
planted cells in mice angiogenesis via suppression of
VEGF–VEGF-R2–Akt signaling axis. These findings
were in accordance with the later reports in which treat-
ment of GS was shown to downregulate the expression
of antiapoptotic gene products including XIAP, survivin,
cFLIP, Bcl-2, Bcl-Xl, c-myc and COX-2 [24, 25]. The
mechanism by which GS-induced apoptosis in prostate
cancer cells is not known, however, GS-mediated gener-
ation of ROS, which leads to activation of JNK has been
implicated as one of the mechanisms leading to cell
death in these cancer cells [24]. Treatment of LNCaP
and PC3 cells with GS-causes the activation of JNK and
p38. Interestingly, GS treatment activates extracellular
signal-regulated kinase 1/2 (ERK1/2) only in LNCaP
cells. GS treatment of prostate cancer cells resulted in
the generation of ROS but not in normal PrEC prostate
cells. In addition, PrEC cells showed resistance to GS-
mediated activation of JNK kinase. Furthermore, over-
expression of catalase and superoxide dismutase in
prostate cancer cells prevented GS-mediated apoptosis
and JNK activation [25]. In another study from the
same group, treatment of prostate cancer cells, LNCaP
withGL, a crude extract from which GS has been
isolated, showed a dose-dependent inhibition of cell
viability [80]. GL-mediated inhibition of cell viability in
prostate cancer cells correlated with apoptosis as sup-
ported by an increase in cytoplasmic histone-associated
DNA fragmentation and cleavage of PARP. Further,
GL-induced apoptosis has been found to be associated
with the generation of ROS and JNK activation along
with the upregulation of proapoptotic proteins Bax and
Bak and downregulation of Bcl-2 expression. During
GS-mediated apoptosis, activation of JNK preceded be-
fore upregulation of Bax activation [80]. It was further
shown that z-GS, another form of GS causes inhibition
of angiogenesis via inactivation of AKT, and suppres-
sion of angiogenic factors such as VEGF and G-CSF
[28]. The growth inhibitory effect of GS in prostate
cancer has also been proposed to be due to inactivation
of ATP citrate lyase (ACL or ACLY) which has been
shown to exhibit crosstalk with the AKT signaling [81].
ACL is an extra-mitochondrial enzyme that has been
demonstrated to play a crucial role in cellular lipogen-
esis, and its dysregulated expression is reported various
cancers such as colon, prostate, liver, lung cancers as
well as in many immortalized cells. Aberrant expression
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of ACL was reported to be inversely associated with
tumor stage as well as differentiation and serves as a
negative prognostic marker [82]. Thus, targeting ACL
with GS in prostate cancermight be of potential thera-
peutic intervention strategy.
Liver, lung and ovarian cancer
It is well-known fact that the growth inhibitory and
proapoptotic effects of GS are mediated through vari-
ous mechanisms and certain cancers share the common
mechanism. In liver cancer, the mechanism of cell
death has been through sensitizing hepatoma cells to
tumor necrosis factor-related apoptosis inducing ligand
(TRAIL) mediated apoptosis. TRAIL at higher doses
has been shown to cause toxicity to the healthy cells in
addition to cytotoxicity to the cancer cells. Therefore
using other agent/drugs in combination with TRAIL
could be a viable strategy to induce maximum cytotoxic
effects at subtoxic doses of TRAIL. It has been shown
that subtoxic doses of GS and TRAIL can generate effi-
cient apoptotic death in hepatoma cells. This GS/TARIL
combination has proved to be efficient in inducing the
apoptosis by disrupting the disrupting mitochondrial
membrane potential resulting in the release of cytochrome
C to the cytosol and consequent activation of caspases. In
addition GS-mediated ROS generation can lead to upreg-
ulation of the death receptor DR5 via eIF2α and C/EBP
homologous protein (CHOP). TRAIL binding to DR5
can result in the efficient induction of TRAIL-mediated
apoptosis in hepatoma cell [83, 84]. GS has been shown
to induce apoptotic cell death in hepatocellular carcin-
oma cell lines by activating intrinsic mitochondrial
pathway [85].
GS was found to have the antifibrotic activity as it me-
diates reduced activation and survival of hepatic stellate
cells (HSCs), which serve as the primary source of the
matrix proteins. Accumulation of extracellular matrix
has been shown to be involved in liver fibrosis that can
lead to cirrhosis of the liver. During cirrhosis, the blood
flow through the liver becomes disrupted due to damage
in an architectural organization of the liver. Once cir-
rhosis is developed, the risk of developing liver cancer is
significantly increased. It was found that the GS inhibits
the growth of immortalized LX-2 HSC cells via induc-
tion of apoptosis. GS-induced apoptosis in HSC was
accompanied by activation of c-Jun N-terminal kinase
and mitochondrial apoptotic signaling. GS-induced HSC
growth inhibition was also found to involve AKT and ad-
enosine monophosphate-activated protein kinase (AMPK)
phosphorylation modifications resulting in the activation
of proapoptotic proteins and downregulation of antia-
poptotic proteins [83]. GS has also been shown to
inhibit NF-κB activation in LX-2 cells where the consti-
tutive activation of this pathway leads to increased
growth of these cells [86]. Besides NF-κB activation, in-
creased collagen α1 synthesis and α-smooth muscle
actin expression plays a significant role in the growth
of HSCs resulting in enhanced liver cirrhosis, and treat-
ment with GS significantly decreased the extent of col-
lagen deposition via inhibiting collagen α1 synthesis
and α-smooth muscle actin expression. These findings
strongly implicate GS as an antifibrotic agent inhibiting
various survival pathways via induction of apoptotic cell
death in HSC cells.
Limited studies have also shown that GS induces anti-
cancer activities in lung and ovarian cancers. Treatment
of lung and ovarian cancer cell lines with GS resulted in
inhibition of cell proliferation and downregulation of
cyclin D1 and cdc2 expression leading to inhibition of
DNA synthesis. In addition GS treatment also increased
the expression of cyclin-dependent kinase inhibitor p21
and p27. Moreover, GS-mediated apoptosis correlated
with the activation of JNK, caspase-cascade, accompan-
ied with inhibition of the expression of various anti-
apoptotic genes [25].
Hematological malignancies
Hematological malignancies constitute approximately
6.5% of all cancer incidences worldwide [87]. The pri-
mary causes of these liquid cancers are due to defect at
the level of bone marrow and lymphatic system [87].
These malignancies are classified into three main
groups including leukemia, lymphoma, and multiple
myeloma (MM). The anticancer activity of GS in these
hematological malignancies is not studied in detail, and
this review would enable to pursue further research in
this field. Antileukemic effect of GS has been reported
by Samudio and colleagues [26] where they examined the
anticancer effects of three isomeric pregnadienedione ste-
roids [i.e., cis-GS, trans-GS, and 16-dehydroprogesterone]
in HL60 and U937 cells as well as in primary leukemic
blasts in culture [26]. They demonstrated that the
treatment of HL60 and U937 cells with these com-
pounds prevented cell proliferation via mitochondrial-
dependent but caspase-independent apoptosis. All
three compounds were shown to induce the generation
of ROS which can be one of their mechanisms of cell
death. Furthermore, these compounds resulted in the
dephosphorylation of constitutive extracellular signal-
regulated kinase phosphorylation status in these
leukemic cells. Interestingly only cis-GS caused a rapid
depletion of glutathione levels as well as oxidation of
the mitochondrial phospholipid cardiolipin [26]. The
other study carried by Shishodia and colleagues [25]
observed that the treatment of leukemia, myeloma and
melanoma cell lines with GS resulted in decreased pro-
liferation along with reduced levels of cyclin D1 and
cdc2 which inhibited DNA synthesis. They found an
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increased levels of cyclin-dependent kinase inhibitor
p21 and p27 as well as induction of apoptosis by acti-
vation of JNK, caspase-cascade, PARP cleavage and
downregulation of anti-apoptotic products [25].
Conclusion
There is a growing evidence now that GS is capable of
preventing tumor growth and proliferation through acti-
vation of pro-apoptotic and inhibition of anti-apoptotic
signaling pathways (Fig. 3). GS has been shown to cause
effects on the biological function of cells including cell
proliferation, angiogenesis, inflammatory response and
apoptotic cells death in cancers cells (Fig. 4). GS medi-
ated anticancer effects are due to inhibition of kinase ac-
tivity of AKT and its downstream targets such as GSK3,
FOXO1 and mTOR signaling. GS has been shown to
inhibit the activity of many transcription factors such as
NF-κB and AP1 that can lead to down regulation of
various gene products including c-myc, Bcl-2, COX-2,
NOS, Cyclin D1, interleukins and MMP-9. Furthermore,
GS affects many growth factor receptors and angiogenic
factors such as VEGF, which play a pivotal role in tumor
growth, metastasis and angiogenesis. Not only GS-induces
apoptosis in cancer cells and inhibits cell proliferation but
it is also useful in reducing the cytotoxicity associated with
conventional chemotherapeutic agents by sensitizing or
causing the additive apoptotic effects. Despite, GS has
been extensively studied, the conclusive mechanisms re-
sponsible for its anticancer effects are still not fully
understood. Outcomes of various preclinical studies sug-
gest that anticancer action of GS and its isomers are due
to combined effects on proliferation and invasiveness in
cancer cells.
Future perspective
The rate of incidence of cancer and resulted deaths are
alarming around the world despite the accessibility of
various therapeutic options for cancer patients. Most
modern medicines currently available for treating cancer
are synthetic, mono-targeted, very expensive, less effi-
cient and often possess severe side effects. Therefore,
there is a critical need to develop alternative drugs for
the management of cancer.
Phytochemicals, a family of naturally occurring com-
pounds including polyphenols, carotenoids and steroids
have been demonstrated to have anticancer activities
against a variety of cancers both in vitro and in vivo.
Among these compounds, guggulsterone (GS), a steroid
by nature recently has attracted the attention of cancer
researchers and investigators for its anticancer poten-
tials. GS has been shown to induce efficient apoptotic
cell death in a variety of cancer cells. Interestingly, no
apoptotic death was seen in healthy cells. A number of
studies further showed significant cellular changes
induced by GS via modulating distinct signaling mole-
cules involved in carcinogen detoxification, cell prolif-
eration, angiogenesis, metastasis, multi-drug resistance,
etc. In addition, GS has been shown to sensitize the
Fig. 3 Schematic diagram illustrating the main biological targets of Guggulsterone. The apoptotic effects of guggulsterone are preceded by
activation of JNK, suppression of Akt and NF-kB activity. Activation of JNK leads to induction of propapoptic proteins and release of cytochrome
c from the mitochondria which in turn activates caspases, resulting in apoptosis. Down regulation of NF-kB activity leads to inhibition of anti
apoptotic proteins which in turn activates caspases, resulting in apoptosis and inhibition of proliferation
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effects of chemotherapeutic drugs in in vitro system.
These anticancer activities in preclinical settings are poten-
tially beneficial in treating cancer. Further studies directed
towards target identification and pathway analysis could
pave the way for the addition of GS to the management of
anticancer therapy. Despite the availability of extensive pre-
clinical data on anticancer potentials of GS, there is a lack
of studies accounting for its safety and bioavailability, which
needs to be pursued. Safety of long-term use of GS needs
to be evaluated in clinical settings, but appears to be devoid
of acute, subacute, chronic toxicity in rats, dogs, and
monkeys; no mutagenic or teratogenic effects have been
reported. Ayurvedic system of medicine describes GS
as safe and efficient medicine; however, it should be
used cautiously in combination with prescribed drugs
as it may modulate the activity of drug metabolizing
enzymes. As soon as a consensus on its safety and bio-
availability emerges, a planned Phase I clinical trials
should be perused to validate its usefulness as antican-
cer agents and must be prioritized for different site-
specific cancers. The outcome of these studies may lead
to development of new and efficient therapeutic trate-
gies for the management of cancer.
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